Amatuximab Biosimilar - Research Grade

Human

MSLN

>1mg/ml

Human IgG1

Misitatug Biosimilar - Research Grade (ICH5688)

https://www.imgt.org/mAb-DB/

ICH3002

Q13421

Blue ice

This product is an unconjugated, non-therapeutic recombinant analog of amatuximab, supplied for research use only and not for human or veterinary use. Amatuximab is a chimeric human/mouse-derived antibody directed against mesothelin (MSLN, UniProt Q13421), a cell-surface glycoprotein over-expressed on many solid tumors. This research-grade analog reproduces the MSLN-directed binding activity of the originator so that laboratories can use it as a defined reagent rather than as a drug. Typical applications include serving as a positive or isotype-matched control in binding and neutralization assays, a benchmarking reagent when characterizing new anti-MSLN candidates, a targeting moiety for antibody-drug-conjugate and CAR construct development, and a tool for studying MSLN biology in vitro and in preclinical models. It is offered as a full-length human IgG1 format. The material is manufactured to research specifications with low endotoxin (research grade less than 1 EU/mg; ultra-low option less than 0.5 EU/mg) and is available in bulk milligram-to-gram quantities to support assay development, scale-up, and reproducible in-vitro and preclinical workflows. Mesothelin (MSLN, UniProt Q13421) is a glycosylphosphatidylinositol-anchored cell-surface glycoprotein. It is synthesized as a ~71 kDa precursor that is proteolytically cleaved into a secreted N-terminal fragment (megakaryocyte potentiating factor) and a membrane-bound C-terminal mesothelin domain. In normal tissue, expression is largely restricted to mesothelial cells lining the pleura, pericardium, and peritoneum, giving it a favorable therapeutic-window profile. Mesothelin is strongly over-expressed in mesothelioma, pancreatic, ovarian, and non-small-cell lung carcinomas. It binds the ovarian-cancer antigen CA125/MUC16, an interaction implicated in cell adhesion, peritoneal metastasis, and tumor progression. Because expression is tumor-enriched and cell-surface accessible, MSLN is a prominent target for antibody, antibody-drug-conjugate, immunotoxin, bispecific, and CAR-T approaches.

CAK1 antigen, Pre-pro-megakaryocyte-potentiating factor, Mesothelin, MPF

Detects human MSLN. This non-therapeutic antibody uses the same sequence as the therapeutic antibody Amatuximab.

This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

Q: Is the Amatuximab biosimilar available in gram quantities?

A: Yes — it is supplied in scalable milligram to gram quantities for heavy-usage and high-throughput laboratories.

Q: Is this research-grade Amatuximab suitable for in vivo studies?

A: Yes, it is a low-endotoxin, in vivo-ready formulation intended for preclinical and in vivo research use only (RUO).

Q: What does the Amatuximab biosimilar target?

A: It is an unconjugated, non-therapeutic analog of Amatuximab that binds human MSLN.